Donostia, 11 July 2023 - VIVEbiotech is a CDMO GMP that develops and manufactures lentiviral vectors from early stage to commercial scale. It is currently working on more than 40 international projects in compliance with FDA and EMA regulations, and is manufacturing vectors for companies based in the US, Europe, Asia and Australia. VIVEbiotech is authorized to manufacture lentiviral vectors for both ex-vivo and in-vivo use.
The MAGIC (next-generation Models And Genetic therapIes for rare neuromusCular diseases) consortium brings together leading international institutions, SMEs and patient advocacy groups to accelerate the development of gene therapies for muscular dystrophies. By creating advanced human quasi vivo models, developing tissue-specific vectors, and exploring gene-editing strategies, the consortium aims to overcome the barriers that have hindered the translation of gene therapies into clinical applications. Through collaboration, innovation and a patient-centred approach, the MAGIC consortium is committed to making a meaningful impact on the lives of individuals affected by muscular dystrophies.